E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The study has two co-primary aims: Aim 1: To test the hypothesis that treatment with empagliflozin, semaglutide or the combination vs. placebo improves arterial function in T2DM patients. Further, we aim to compare the different treatment modalities with each other (empagliflozin vs semaglutide, combination vs semaglutide, combination vs empagliflozin). The main outcome is change in arterial stiffness assessed as carotid-femoral PWV.
Aim 2: To test the hypothesis that treatment with empagliflozin, semaglutide or the combination vs. placebo improves renal oxygenation in T2DM patients. Further, we aim to compare the different treatment modalities with each other (empagliflozin vs semaglutide, combination vs semaglutide, combination vs empagliflozin). The main outcome is change in renal oxygenation assesed by magnetic resonance imaging (MRI). |
|
E.2.2 | Secondary objectives of the trial |
Aim 3: To test the hypothesis that treatment with empagliflozin, semaglutide or the combination vs. placebo improves platelet function in T2DM patients. Further, we aim to compare the different treatment modalities with each other (empagliflozin vs semaglutide, combination vs semaglutide, combination vs empagliflozin).
Aim 4: To test the hypothesis that treatment with empagliflozin, semaglutide or the combination vs. placebo improves glycemic control in T2DM patients. Further, we aim to compare the different treatment modalities with each other (empagliflozin vs semaglutide, combination vs semaglutide, combination vs empagliflozin).
Aim 5: To test the effect of empagliflozin, semaglutide or the combination vs. Placebo on retinal metabolism and flow. Further, we aim to compare the different treatment modalities with each other (empagliflozin vs semaglutide, combination vs semaglutide, combination vs empagliflozin). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Diagnose of type 2 diabetes. HbA1c level of 7% (53 mmol/mol) or more. Age of 50 years or more with established cardiovascular disease (prior myocardial infarction, prior stroke or prior transient ischemic attack, prior coronary, carotid or peripheral arterial revascularization, more than 50 % stenosis on angiography or imaging of coronary, carotid or lower extremities arteries, history of symptomatic coronary heart disease documented by e.g. positive exercise stress test or any cardiac imaging or unstable angina with electrocardiography (ECG) changes), or chronic heart failure (New York Heart Association class II or III). or Age of 60 years or more with at least one cardiovascular risk factor (persistent microalbuminuria (30-299 mg/g) or proteinuria, hypertension and left ventricular hypertrophy by electrogram or imaging, left ventricular systolic or diastolic dysfunction by imaging or ankle/brachial index less than 0.9).
|
|
E.4 | Principal exclusion criteria |
Estimated glomerular filtration rate < 60 ml/min. Treatment with a SGLT2-inhibitor, GLP-1-receptor agonist or dipeptidyl-peptidase 4 inhibitor within 30 days before screening or insulin other than basal or premixed within 30 days before screening. A history of an acute coronary or cerebrovascular event within 90 days before randomization. Planned revascularization of a coronary, carotid, or peripheral artery. Inability to give informed consent. Active cancer diagnosis other than basal cell carcinoma. Indication of liver disease (serum ALAT, ASAT or alkaline phosphatase above 3 x upper limit). Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption. Treatment with systemic steroids at time of randomization. Change in dosage of thyroid hormones within 6 weeks prior to screening. Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake. Chronic or acute pancreatitis. Pregnancy or breastfeeding. Allergy to either empagliflozin or semaglutide or any of the excipients contained in the drugs.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is change in arterial stiffness assessed as carotid-femoral PWV and change in renal oxygenation assesed by magnetic resonance imaging (MRI). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Endpoints will be evaluated at baseline, after 16 weeks of treatment and after 32 weeks of treatments. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints to Aim 1: Change in endothelial function, ambulatory PWV and central Blood Pressure indices and ambulatory Blood Pressure.
Secondary endpoints to Aim 2: Change in glomerular filtration rate (GFR), renal plasma flow (RPF), corticomedullary sodium homeostasis and markers of the renin-angiotensin system. Change in urinary albumin excretion and urine-Prostaglandin E (PGE)
Secondary endpoints to Aim 3: Change in platelet aggregation, Platelet count and turnover
Secondary endpoints to Aim 4: Change in mean glucose level and glucose variability assessed by continuous glucose monitoring (CGM) and HbA1c. Change in Insulin sensitivity, beta-cell responsitivity and hepatic insulin extraction evaluated by the oral minimal model method using an oral glucose tolerance test with multiple bloodsampling. Change in Betahydroxybutyrat levels.
Secondary endpoints to Aim 5: Change in retinal oxygenation, metabolism and flow assed by oximetry and retinal arterial and venolar vasomotion assessed by Retinal Vessel Analyzer (RVA). Change in retinal thickness assessed by Optical Coherence Tomography (OCT)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Endpoints will be evaluated at baseline, after 16 weeks of treatment and after 32 weeks of treatments. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Semaglutide treatment is open-label and empagliflozin is double-blind |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
7 weeks after the last visit of the last subject.
Semaglutide has a long half-life. We will collect information of adverse events and adverse reactions until 7 weeks after the last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |